185 related articles for article (PubMed ID: 18055202)
1. (Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2008 Jan; 18(2):640-4. PubMed ID: 18055202
[TBL] [Abstract][Full Text] [Related]
2. (Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3930-4. PubMed ID: 17517507
[TBL] [Abstract][Full Text] [Related]
3. (Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jun; 17(12):3292-7. PubMed ID: 17452102
[TBL] [Abstract][Full Text] [Related]
4. Aminocyclohexylsulfonamides: discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Cai H; Connolly PJ; Peng S; Stauber K; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Nov; 17(22):6123-8. PubMed ID: 17904840
[TBL] [Abstract][Full Text] [Related]
5. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
6. 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective alpha-1a/1d adrenergic receptor ligands.
Li S; Chiu G; Pulito VL; Liu J; Connolly PJ; Middleton SA
Bioorg Med Chem Lett; 2007 Mar; 17(6):1646-50. PubMed ID: 17254786
[TBL] [Abstract][Full Text] [Related]
7. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
8. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
Roehrborn CG; Schwinn DA
J Urol; 2004 Mar; 171(3):1029-35. PubMed ID: 14767264
[TBL] [Abstract][Full Text] [Related]
9. Alpha1 adrenergic receptor blockade in the male lower urinary tract and other body systems.
Andersson KE
Scand J Urol Nephrol Suppl; 1995; 168():13-9. PubMed ID: 7541547
[TBL] [Abstract][Full Text] [Related]
10. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
11. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S; Benzeroual KE
Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
[TBL] [Abstract][Full Text] [Related]
12. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
Nagarathnam D; Wetzel JM; Miao SW; Marzabadi MR; Chiu G; Wong WC; Hong X; Fang J; Forray C; Branchek TA; Heydorn WE; Chang RS; Broten T; Schorn TW; Gluchowski C
J Med Chem; 1998 Dec; 41(26):5320-33. PubMed ID: 9857099
[TBL] [Abstract][Full Text] [Related]
14. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
Pulito VL; Li X; Varga SS; Mulcahy LS; Clark KS; Halbert SA; Reitz AB; Murray WV; Jolliffe LK
J Pharmacol Exp Ther; 2000 Jul; 294(1):224-9. PubMed ID: 10871316
[TBL] [Abstract][Full Text] [Related]
15. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the studies of alpha1-receptor blocker for benign prostatic hyperplasia].
Sun Y
Zhonghua Nan Ke Xue; 2004 Jul; 10(7):483-5. PubMed ID: 15354512
[TBL] [Abstract][Full Text] [Related]
17. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
18. 1,2,4-Benzothiadiazine derivatives as alpha1 and 5-HT1A receptor ligands.
Tait A; Luppi A; Franchini S; Preziosi E; Parenti C; Buccioni M; Marucci G; Leonardi A; Poggesi E; Brasili L
Bioorg Med Chem Lett; 2005 Feb; 15(4):1185-8. PubMed ID: 15686938
[TBL] [Abstract][Full Text] [Related]
19. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
20. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]